Abstract

Photodynamic therapy (PDT) is a promising treatment option that ablates cancerous cells and tumors via photoinduced sensitization of singlet oxygen. Over the last few decades, much work has been devoted to the development of new photochemotherapeutic agents for PDT. A wide variety of macrocyclic tetrapyrrole based photosensitizers have been designed, synthesized and characterized as PDT agents. Many of these complexes have a variety of issues that pose a barrier to their use in humans, including biocompatibility, inherent toxicity, and synthetic hurdles. We have developed a non-traditional, non-cyclic, and non-aromatic tetrapyrrole ligand scaffold, called the biladiene (DMBil1), as an alternative to these traditional photosensitizer complexes. Upon insertion of a heavy atom such as Pd2+ center, Pd[DMBil1] generates singlet oxygen in substantial yields (ΦΔ = 0.54, λexc = 500 nm) when irradiated with visible light. To extend the absorption profile for Pd[DMBil1] deeper into the phototherapeutic window, the tetrapyrrole was conjugated with alkynyl phenyl groups at the 2- and 18-positions (Pd[DMBil2-PE]) resulting in a significant redshift while also increasing singlet oxygen generation (ΦΔ = 0.59, 600 nm). To further modify the dialkynyl-biladiene scaffold, we conjugated a 1,8-diethynylanthracene with to the Pd[DMBil1] tetrapyrrole in order to further extend the compound’s π-conjugation in a cyclic loop that spans the entire tetrapyrrole unit. This new compound (Pd[DMBil2-P61]) is structurally reminiscent of the P61 Black Widow aircraft and absorbs light into the phototherapeutic window (600–900 nm). In addition to detailing the solid-state structure and steady-state spectroscopic properties for this new biladiene, photochemical sensitization studies demonstrated that Pd[DMBil2-P61] can sensitize the formation of 1O2 with quantum yields of ΦΔ = 0.84 upon irradiation with light λ = 600 nm. These results distinguish the Pd[DMBil2-P61] platform as the most efficient biladiene-based singlet oxygen photosensitizer developed to date. When taken together, the improved absorption in the phototherapeutic window and high singlet oxygen sensitization efficiency of Pd[DMBil2-P61] mark this compound as a promising candidate for future study as an agent of photodynamic cancer therapy.

Highlights

  • Photodynamic therapy (PDT) is an alternative treatment option for various types of cancers [1,2], whereby a photosensitizer is administered to a patient, and the treatment site is selectively irradiated with light of a particular wavelength [3]

  • Much work has been dedicated to the development of new agents for PDT that absorb strongly in the phototherapeutic window and generate significant amounts of singlet oxygen

  • We have previously reported that biladienes are oligotetrapyrroles that upon coordination to Pd2+

Read more

Summary

Introduction

Photodynamic therapy (PDT) is an alternative treatment option for various types of cancers [1,2], whereby a photosensitizer is administered to a patient, and the treatment site is selectively irradiated with light of a particular wavelength [3]. Much research has gone into developing new photosensitizers for PDT against cancer [11,12,13], microbes/viruses [14,15,16], and for various dermatological applications [17] Many of these complexes are comprised of cyclic, aromatic tetrapyrroles that absorb strongly in the phototherapeutic window (600–900 nm) [18,19,20]. We report an concise synthetic route to the Pd[DMBil2-P61] complex, which is subjected to full structural and steady state spectroscopic analysis These results demonstrate that this new biladiene bearing a dialkynylanthracene bridge at the 2- and. For newlyprior synthesized compounds are provided in the Supplementary Materials

F NMR spectra were at 25
X-ray Crystallography
UV-Vis Absorption Experiments
Emission Experiments
Singlet Oxygen Experiments
Resultsto and Discussion was selectively brominated at the
Conclusions and Future Directions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call